The FDA has published new scientific research confirming that trace metals found in tampons are present in amounts too small to cause harm during use. This July 2026 study, published in the peer-reviewed journal Toxicological Sciences, represents part of a broader regulatory shift toward more rigorous safety testing of menstrual products, including new guidance on contaminant evaluation and ingredient transparency that the agency is finalizing this year.

What Is the FDA Actually Testing for in Menstrual Products?

For decades, menstrual product safety relied on outdated regulatory frameworks. The FDA's current approach to tampon and pad oversight traces back to 2005 guidance that focused primarily on performance and labeling. But in October 2025, the agency issued draft guidance titled "Menstrual Products: Performance Testing and Labeling Recommendations," which signals a significant expansion in what manufacturers must evaluate before products reach consumers.

The new draft guidance moves beyond the narrow focus on metals and addresses a much wider range of potential contaminants. When finalized, this updated guidance will replace the 2005 framework and require manufacturers to demonstrate that their products are safe and effective through more comprehensive testing protocols. The shift reflects growing consumer and scientific interest in understanding exactly what chemicals and materials are present in products that contact sensitive tissue for extended periods.

How Are Regulators Improving Safety Assessment Methods?

The FDA's Biocompatibility and Toxicology Program, housed within the Center for Devices and Radiological Health, is actively developing new testing approaches to evaluate medical devices and products that contact the human body. This program addresses several key gaps in how safety is currently assessed:

• Alternative Testing Methods: The FDA is validating and qualifying new approach methodologies, or NAMs, which include laboratory tests, computational models, and other approaches that can predict how products interact with the body without relying solely on traditional animal testing.
• Chemical Detection and Analysis: Researchers are improving methods for detecting a wide range of chemical properties in products, ensuring that contaminants across different categories can be identified and measured consistently.
• Predictive Modeling: The program is developing physics-based computer simulations that can predict which chemicals might leach from materials used in menstrual products, allowing regulators to identify potential risks before products are tested on consumers.

These methodological improvements matter because they make safety assessments more consistent, reproducible, and comprehensive. Rather than relying on a single test or a narrow set of contaminants, regulators can now evaluate products for a broader spectrum of potential chemical exposures.

What Does This Mean for Ingredient Transparency?

One of the most significant changes in the draft guidance is its emphasis on promoting transparency in menstrual product ingredients. Currently, manufacturers are not required to disclose the full list of materials and chemicals used in tampons, pads, or other menstrual products. This lack of transparency has been a major frustration for consumers and public health advocates who want to make informed choices about products that contact their bodies for multiple days each month.

The new FDA guidance recommendations push manufacturers toward greater openness about what goes into their products. This aligns with broader consumer demand for ingredient disclosure in personal care items and reflects a recognition that people deserve to know what they're using. The guidance also emphasizes evaluating products for contaminants, which means manufacturers will need to test for unwanted substances that may be present as byproducts of manufacturing or sourcing.

The timing of this regulatory evolution is significant. As scientific interest in menstrual product safety has grown, so has consumer awareness of potential chemical exposures. The FDA's new research and updated guidance represent an acknowledgment that the previous regulatory approach was insufficient for modern safety standards.

When Will These New Standards Take Effect?

The draft guidance released in October 2025 is still in the comment period, meaning the FDA is accepting feedback from manufacturers, consumer advocates, and the public before finalizing the document. Once finalized, the new guidance will supersede the 2005 framework and establish the baseline for how menstrual products must be evaluated going forward.

The FDA's July 2026 study on metals in tampons serves as an example of the kind of rigorous, peer-reviewed research that will likely inform future safety standards. By publishing findings in a scientific journal rather than simply issuing regulatory statements, the agency is contributing to the broader scientific literature on menstrual product safety and inviting scrutiny from the research community.

For consumers, these regulatory developments suggest that menstrual product safety is receiving more attention than it has in years. The combination of new testing methods, emphasis on ingredient transparency, and peer-reviewed research indicates a shift toward treating menstrual products with the same safety rigor applied to other medical devices that contact the body. While the new guidance is not yet final, its trajectory suggests that future menstrual products will be subject to more comprehensive safety evaluation than those currently on shelves.